Skip to main content
SpringerLink
Log in

Kombination punktet in der Second-Line-Therapie des Magenkarzinoms

  • Literatur kompakt_Gastrointestinale Tumoren
  • Published:
Im Focus Onkologie Aims and scope

In einer Phase-III-Studie verglichen japanische Kollegen die Kombination von Irinotecan und Cisplatin mit der alleinigen ­Irinotecan-Gabe als Second-Line-Chemotherapie bei fortgeschrittenem Magenkarzinom.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1

Literatur

  • Higuchi K et al. Biweekly irinotecan plus cisplatin versus irinotecan alone as second-line treatment for advanced gastric cancer: A randomised phase III trial (TCOG GI-0801/BIRIP trial). Eur J Cancer. 2014;50(8):1437-45.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. http://www.springermedizin.de

    Judith Neumaier

Authors
  1. Judith Neumaier
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Neumaier, J. Kombination punktet in der Second-Line-Therapie des Magenkarzinoms. Im Focus Onkologie 17, 23 (2014). https://doi.org/10.1007/s15015-014-1205-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15015-014-1205-z

Search

Navigation